Loading…
Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study
Summary Background Reports have indicated that the use of statins may ameliorate the course of cirrhosis. Aim To determine the relationship between use of statins and mortality rate in patients with cirrhosis. Methods We did a retrospective case‐cohort analysis based on data from the Danish register...
Saved in:
Published in: | Alimentary pharmacology & therapeutics 2017-10, Vol.46 (7), p.673-680 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3 |
container_end_page | 680 |
container_issue | 7 |
container_start_page | 673 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 46 |
creator | Bang, U. C. Benfield, T. Bendtsen, F. |
description | Summary
Background
Reports have indicated that the use of statins may ameliorate the course of cirrhosis.
Aim
To determine the relationship between use of statins and mortality rate in patients with cirrhosis.
Methods
We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate.
Results
A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death.
Conclusions
Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis.
Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364. |
doi_str_mv | 10.1111/apt.14243 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1936622509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1936208281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</originalsourceid><addsrcrecordid>eNp10ctqGzEUBmBREhrH7aIvUATdJItxdJmLtDSmSQuBlJKuB43mGCsdS1OdGYx3fYKQZ8yTVPakXRSijW4fP0I_IR84W_A0rkw_LHgucvmGzLgsi0wwWZ6QGROlzoTi8oycIz4wxsqKibfkTCilWJ7rGXn8Du1ooaXR4U8a1rQFG7Y9eDSDC54a36YjM2yoQQzWmSHZnUv7EeHgcUjQI3We9mkFfsDp3nQ2bELnLLUuxk1Ahwu6pP6Yu3MtUGsQnn8_HVgcUtDY7t-R07XpEN6_zHPy4_rz_epLdnt383W1vM2sVEpmeVPoqoEKGrXmWum8EqaogGuRvkFXhWlyISwDpW0pGsMaowopSrCyLcAqI-fkYsrtY_g1Ag711qGFrjMewog117IshSiYTvTTf_QhjNGn1x2VYOrww3NyOSkbA2KEdd1HtzVxX3NWH0qqU0n1saRkP74kjs0W2n_ybysJXE1g5zrYv55UL7_dT5F_AHYjnfc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1936208281</pqid></control><display><type>article</type><title>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</title><source>Wiley</source><creator>Bang, U. C. ; Benfield, T. ; Bendtsen, F.</creator><creatorcontrib>Bang, U. C. ; Benfield, T. ; Bendtsen, F.</creatorcontrib><description>Summary
Background
Reports have indicated that the use of statins may ameliorate the course of cirrhosis.
Aim
To determine the relationship between use of statins and mortality rate in patients with cirrhosis.
Methods
We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate.
Results
A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death.
Conclusions
Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis.
Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14243</identifier><identifier>PMID: 28880449</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Cirrhosis ; Classification ; Cohort analysis ; Cohort Studies ; Data processing ; Death ; Female ; Females ; Health risk assessment ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Liver cirrhosis ; Liver Cirrhosis, Alcoholic - drug therapy ; Male ; Middle Aged ; Mortality ; Propensity Score ; Retrospective Studies ; Statins</subject><ispartof>Alimentary pharmacology & therapeutics, 2017-10, Vol.46 (7), p.673-680</ispartof><rights>2017 John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</citedby><cites>FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</cites><orcidid>0000-0003-0696-6124</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28880449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bang, U. C.</creatorcontrib><creatorcontrib>Benfield, T.</creatorcontrib><creatorcontrib>Bendtsen, F.</creatorcontrib><title>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Reports have indicated that the use of statins may ameliorate the course of cirrhosis.
Aim
To determine the relationship between use of statins and mortality rate in patients with cirrhosis.
Methods
We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate.
Results
A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death.
Conclusions
Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis.
Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.</description><subject>Adult</subject><subject>Aged</subject><subject>Cirrhosis</subject><subject>Classification</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Data processing</subject><subject>Death</subject><subject>Female</subject><subject>Females</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis, Alcoholic - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Propensity Score</subject><subject>Retrospective Studies</subject><subject>Statins</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp10ctqGzEUBmBREhrH7aIvUATdJItxdJmLtDSmSQuBlJKuB43mGCsdS1OdGYx3fYKQZ8yTVPakXRSijW4fP0I_IR84W_A0rkw_LHgucvmGzLgsi0wwWZ6QGROlzoTi8oycIz4wxsqKibfkTCilWJ7rGXn8Du1ooaXR4U8a1rQFG7Y9eDSDC54a36YjM2yoQQzWmSHZnUv7EeHgcUjQI3We9mkFfsDp3nQ2bELnLLUuxk1Ahwu6pP6Yu3MtUGsQnn8_HVgcUtDY7t-R07XpEN6_zHPy4_rz_epLdnt383W1vM2sVEpmeVPoqoEKGrXmWum8EqaogGuRvkFXhWlyISwDpW0pGsMaowopSrCyLcAqI-fkYsrtY_g1Ag711qGFrjMewog117IshSiYTvTTf_QhjNGn1x2VYOrww3NyOSkbA2KEdd1HtzVxX3NWH0qqU0n1saRkP74kjs0W2n_ybysJXE1g5zrYv55UL7_dT5F_AHYjnfc</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Bang, U. C.</creator><creator>Benfield, T.</creator><creator>Bendtsen, F.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0696-6124</orcidid></search><sort><creationdate>201710</creationdate><title>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</title><author>Bang, U. C. ; Benfield, T. ; Bendtsen, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cirrhosis</topic><topic>Classification</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Data processing</topic><topic>Death</topic><topic>Female</topic><topic>Females</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis, Alcoholic - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Propensity Score</topic><topic>Retrospective Studies</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bang, U. C.</creatorcontrib><creatorcontrib>Benfield, T.</creatorcontrib><creatorcontrib>Bendtsen, F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bang, U. C.</au><au>Benfield, T.</au><au>Bendtsen, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2017-10</date><risdate>2017</risdate><volume>46</volume><issue>7</issue><spage>673</spage><epage>680</epage><pages>673-680</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Reports have indicated that the use of statins may ameliorate the course of cirrhosis.
Aim
To determine the relationship between use of statins and mortality rate in patients with cirrhosis.
Methods
We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate.
Results
A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death.
Conclusions
Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis.
Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28880449</pmid><doi>10.1111/apt.14243</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0696-6124</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 2017-10, Vol.46 (7), p.673-680 |
issn | 0269-2813 1365-2036 |
language | eng |
recordid | cdi_proquest_miscellaneous_1936622509 |
source | Wiley |
subjects | Adult Aged Cirrhosis Classification Cohort analysis Cohort Studies Data processing Death Female Females Health risk assessment Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Liver cirrhosis Liver Cirrhosis, Alcoholic - drug therapy Male Middle Aged Mortality Propensity Score Retrospective Studies Statins |
title | Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T04%3A10%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20risk%20of%20decompensation%20and%20death%20associated%20with%20use%20of%20statins%20in%20patients%20with%20alcoholic%20cirrhosis.%20A%20nationwide%20case%E2%80%90cohort%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Bang,%20U.%20C.&rft.date=2017-10&rft.volume=46&rft.issue=7&rft.spage=673&rft.epage=680&rft.pages=673-680&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14243&rft_dat=%3Cproquest_cross%3E1936208281%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1936208281&rft_id=info:pmid/28880449&rfr_iscdi=true |